Van Roey M - Search Results

1

Regulation of gene expression in vivo following transduction by two separate rAAV vectors.

Rendahl KG, Leff SE, Otten GR, Spratt SK, Bohl D, Van Roey M, Donahue BA, Cohen LK, Mandel RJ, Danos O, Snyder RO. Rendahl KG, et al. Among authors: van roey m. Nat Biotechnol. 1998 Aug;16(8):757-61. doi: 10.1038/nbt0898-757. Nat Biotechnol. 1998. PMID: 9702775

2

Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.

Harding TC, Koprivnikar KE, Tu GH, Zayek N, Lew S, Subramanian A, Sivakumaran A, Frey D, Ho K, VanRoey MJ, Nichols TC, Bellinger DA, Yendluri S, Waugh J, McArthur J, Veres G, Donahue BA. Harding TC, et al. Gene Ther. 2004 Jan;11(2):204-13. doi: 10.1038/sj.gt.3302142. Gene Ther. 2004. PMID: 14712305

3

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.

Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD. Moskalenko M, et al. Among authors: van roey m. J Virol. 2000 Feb;74(4):1761-6. doi: 10.1128/jvi.74.4.1761-1766.2000. J Virol. 2000. PMID: 10644347 Free PMC article.

4

Stable antibody expression at therapeutic levels using the 2A peptide.

Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K. Fang J, et al. Nat Biotechnol. 2005 May;23(5):584-90. doi: 10.1038/nbt1087. Epub 2005 Apr 17. Nat Biotechnol. 2005. PMID: 15834403

5

Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.

Ge Y, Powell S, Van Roey M, McArthur JG. Ge Y, et al. Among authors: van roey m. Blood. 2001 Jun 15;97(12):3733-7. doi: 10.1182/blood.v97.12.3733. Blood. 2001. PMID: 11389010 Free article.

6

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.

Fang J, Yi S, Simmons A, Tu GH, Nguyen M, Harding TC, VanRoey M, Jooss K. Fang J, et al. Mol Ther. 2007 Jun;15(6):1153-9. doi: 10.1038/sj.mt.6300142. Epub 2007 Mar 20. Mol Ther. 2007. PMID: 17375065 Free article.

7

AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma.

Harding TC, Lalani AS, Roberts BN, Yendluri S, Luan B, Koprivnikar KE, Gonzalez-Edick M, Huan-Tu G, Musterer R, VanRoey MJ, Ozawa T, LeCouter RA, Deen D, Dickinson PJ, Jooss K. Harding TC, et al. Mol Ther. 2006 May;13(5):956-66. doi: 10.1016/j.ymthe.2006.02.004. Epub 2006 Mar 31. Mol Ther. 2006. PMID: 16580881 Free article.

8

Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy.

Lalani AS, Chang B, Lin J, Case SS, Luan B, Wu-Prior WW, VanRoey M, Jooss K. Lalani AS, et al. Mol Ther. 2004 Jan;9(1):56-66. doi: 10.1016/j.ymthe.2003.10.001. Mol Ther. 2004. PMID: 14741778 Free article.

9

The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene.

Patel SD, Tran AC, Ge Y, Moskalenko M, Tsui L, Banik G, Tom W, Scott M, Chen L, Van Roey M, Rivkin M, Mendez M, Gyuris J, McArthur JG. Patel SD, et al. Among authors: van roey m. Mol Ther. 2000 Aug;2(2):161-9. doi: 10.1006/mthe.2000.0106. Mol Ther. 2000. PMID: 10947944 Free article.

10

Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.

Robinson M, Li B, Ge Y, Ko D, Yendluri S, Harding T, VanRoey M, Spindler KR, Jooss K. Robinson M, et al. J Virol. 2009 Apr;83(8):3450-62. doi: 10.1128/JVI.02561-08. Epub 2009 Feb 4. J Virol. 2009. PMID: 19193803 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters